Uncategorized
FDA grants Hemera’s dry AMD gene therapy safe to proceed status
Hemera Biosciences’ investigative new drug application for HMR59 has been granted safe to proceed status from the FDA, the company announced in a press release.HMR59, an AAV2 gene therapy, blocks complement overactivity by inhibiting membrane attack complex, the release said.